Thursday 16 October, 2025
Introduction: Genmab has developed a range of Fc-mutation-based antibody platforms. The HexaBody® platform enables the creation of potent therapeutics that…
Read morePoster: Drug/Disease Modelling - Oncology
Exploration of optimal monoclonal antibody properties using a target-mediated drug disposition framework and the InSilicoTrials’ platform for study design simulations
Thursday 16 October, 2025
Introduction: STRO-501 is a humanized murine monoclonal Immunoglobulin 1 (IgG1) antibody (mAb) under pre-clinical development by StromaCare. It targets the…
Read moreA minimal physiologically-based pharmacokinetic/pharmacodynamic mouse xenograft model to inform the evaluation of 212Pb-based Radio-DARPins targeting DLL3
Thursday 16 October, 2025
Introduction/Objectives: MP0712 is a novel radiopharmaceutical candidate composed of a Designed Ankyrin Repeat Protein (DARPin) vector targeting DLL3 and the…
Read moreA semi-mechanistic pharmacokinetic-pharmacodynamic model to characterize thrombocytopenia in patients with biliary tract cancer, and advanced or metastatic solid tumors for a selective antagonist of MDM2-p53 interaction
Thursday 16 October, 2025
Introduction: Brigimadlin (BI 907828) is a murine double minute 2 (MDM2)-tumor suppressor protein p53 (TP53) (MDM2-p53) antagonist developed for the…
Read moreQuantitative Modeling of Radiation-Induced Immune Response in Normal Lung Tissue
Thursday 16 October, 2025
Introduction: Radiation therapy (RT) is a cornerstone in the treatment of cancers such as lung, pancreatic, and breast cancer. However,…
Read moreCharacterising the effect of sex differences in the exposure and safety profile of anticancer chemotherapies
Thursday 16 October, 2025
Introduction: In oncology, male and female patients have historically been treated as equals. Consequently, sex-based differences in treatment effects have…
Read moreExposure–Response Analyses of Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Thursday 16 October, 2025
Objective Erdafitinib (Balversa ®) is a selective pan–fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, approved to treat adult patients…
Read moreQuantitative evaluation of RC-106 antitumor activity in GBM spheroids through tumor growth inhibition modeling based on cell counts data
Thursday 16 October, 2025
Introduction: Glioblastoma (GBM) is an aggressive brain tumor for which there is no cure, highlighting the urgent need for new…
Read moreApplication of a population pharmacokinetic model of olaparib in patients with recurrent glioblastoma and non-small cell lung cancer
Thursday 16 October, 2025
Background: Clinical studies combining molecularly-targeted drugs with radiotherapy have largely failed to improve patient outcomes in cancer. A potential reason…
Read morePopulation Pharmacokinetics of Busulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation
Thursday 16 October, 2025
Background and objectives: Busulfan is a bifunctional alkylating that is commonly used in conditioning regimens prior to allogeneic hematopoietic stem…
Read more